Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2023

22-12-2022 | Diabetic Foot | Research article

Hypertonic saline solution 5% as an effective cost-beneficial alternative to normal saline for wound healing in patients with diabetic lower-extremity ulcers: a randomized controlled trial

Authors: Bizhan Ziaian, Samad Khezri, Armin Amirian, Keivan Ranjbar, Reza Shahriarirad, Mariye Eskandari Kohnaki

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2023

Login to get access

Abstract

Background

Diabetic foot ulcer is among the most common complications and causes of mortality and morbidity in patients with diabetes. Herein, we propose using 5% Hypertonic Solution as an alternative to Normal Saline in treating patients with diabetic foot ulcers as an effective cost-benefit therapeutic approach.

Methods

In this clinical trial, 100 patients with diabetic foot ulcers were divided into two groups. Foot ulcer was washed and treated three times a day with the 5% hypertonic saline solution in the first group, while the second group was treated with normal saline 0.9% and normal washing. Patients were examined for the size and depth of the wound weekly, and the results were recorded after six weeks.

Results

The mean length and width of the wound in the experimental group significantly decreased six weeks after the start of treatment with hypertonic saline (p < 0.05). The wound healing rate was lower after treatment in both groups of patients who had a longer disease duration and higher HbA1c.

Conclusion

Treating diabetic foot ulcers with hypertonic saline solution may help improve wound healing. Therefore, rinsing with hypertonic saline is a cheap, safe, simple, and non-invasive treatment protocol for these patients.
Literature
1.
2.
go back to reference Shahbazian H, Yazdanpanah L, Latifi SM. Risk assessment of patients with diabetes for foot ulcers according to risk classification consensus of International Working Group on Diabetic Foot (IWGDF). Pak J Med Sci. 2013;29(3):730–4.CrossRefPubMedPubMedCentral Shahbazian H, Yazdanpanah L, Latifi SM. Risk assessment of patients with diabetes for foot ulcers according to risk classification consensus of International Working Group on Diabetic Foot (IWGDF). Pak J Med Sci. 2013;29(3):730–4.CrossRefPubMedPubMedCentral
3.
go back to reference Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.CrossRefPubMed Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.CrossRefPubMed
4.
go back to reference Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21.CrossRefPubMed Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21.CrossRefPubMed
5.
go back to reference Aalaa M, Malazy OT, Sanjari M, Peimani M, Mohajeri-Tehrani M. Nurses’ role in diabetic foot prevention and care; a review. J Diabetes Metab Disord. 2012;11(1):24.CrossRefPubMedPubMedCentral Aalaa M, Malazy OT, Sanjari M, Peimani M, Mohajeri-Tehrani M. Nurses’ role in diabetic foot prevention and care; a review. J Diabetes Metab Disord. 2012;11(1):24.CrossRefPubMedPubMedCentral
6.
go back to reference Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, et al. Diabetic foot ulcers: part II. Management. J Am Acad Dermatol. 2014;70(1):21. e1-4; quiz 45 – 6.CrossRef Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, et al. Diabetic foot ulcers: part II. Management. J Am Acad Dermatol. 2014;70(1):21. e1-4; quiz 45 – 6.CrossRef
7.
go back to reference Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet. 2005;366(9498):1725–35.CrossRefPubMed Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet. 2005;366(9498):1725–35.CrossRefPubMed
8.
go back to reference Bakri FG, Allan AH, Khader YS, Younes NA, Ajlouni KM. Prevalence of diabetic foot ulcer and its associated risk factors among diabetic patients in Jordan. Jordan Med J. 2012;171(785):1–16. Bakri FG, Allan AH, Khader YS, Younes NA, Ajlouni KM. Prevalence of diabetic foot ulcer and its associated risk factors among diabetic patients in Jordan. Jordan Med J. 2012;171(785):1–16.
9.
go back to reference Leone S, Pascale R, Vitale M, Esposito S. [Epidemiology of diabetic foot]. Infez Med. 2012;20(Suppl 1(Suppl 1):8–13.PubMed Leone S, Pascale R, Vitale M, Esposito S. [Epidemiology of diabetic foot]. Infez Med. 2012;20(Suppl 1(Suppl 1):8–13.PubMed
10.
go back to reference Nather A, Bee CS, Huak CY, Chew JL, Lin CB, Neo S, et al. Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complications. 2008;22(2):77–82.CrossRefPubMed Nather A, Bee CS, Huak CY, Chew JL, Lin CB, Neo S, et al. Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complications. 2008;22(2):77–82.CrossRefPubMed
11.
go back to reference Richard JL, Schuldiner S. Épidémiologie du pied diabétique. La Revue de Médecine Interne. 2008;29:222-S30.CrossRef Richard JL, Schuldiner S. Épidémiologie du pied diabétique. La Revue de Médecine Interne. 2008;29:222-S30.CrossRef
12.
go back to reference Biswas A, Bharara M, Hurst C, Gruessner R, Armstrong D, Rilo H. Use of sugar on the healing of diabetic ulcers: a review. J Diabetes Sci Technol. 2010;4(5):1139–45.CrossRefPubMedPubMedCentral Biswas A, Bharara M, Hurst C, Gruessner R, Armstrong D, Rilo H. Use of sugar on the healing of diabetic ulcers: a review. J Diabetes Sci Technol. 2010;4(5):1139–45.CrossRefPubMedPubMedCentral
13.
go back to reference Bowling FL, Crews RT, Salgami E, Armstrong DG, Boulton AJ. The use of superoxidized aqueous solution versus saline as a replacement solution in the versajet lavage system in chronic diabetic foot ulcers: a pilot study. J Am Podiatr Med Assoc. 2011;101(2):124–6.CrossRefPubMed Bowling FL, Crews RT, Salgami E, Armstrong DG, Boulton AJ. The use of superoxidized aqueous solution versus saline as a replacement solution in the versajet lavage system in chronic diabetic foot ulcers: a pilot study. J Am Podiatr Med Assoc. 2011;101(2):124–6.CrossRefPubMed
14.
go back to reference Ahmadishooli A, Davoodian P, Shoja S, Ahmadishooli B, Dadvand H, Hamadiyan H, et al. Frequency and Antimicrobial susceptibility patterns of Diabetic Foot infection of patients from Bandar Abbas District, Southern Iran. J Pathog. 2020;2020:1057167.CrossRefPubMedPubMedCentral Ahmadishooli A, Davoodian P, Shoja S, Ahmadishooli B, Dadvand H, Hamadiyan H, et al. Frequency and Antimicrobial susceptibility patterns of Diabetic Foot infection of patients from Bandar Abbas District, Southern Iran. J Pathog. 2020;2020:1057167.CrossRefPubMedPubMedCentral
15.
go back to reference Vileikyte L. Diabetic foot ulcers: a quality of life issue. Diabetes Metab Res Rev. 2001;17(4):246–9.CrossRefPubMed Vileikyte L. Diabetic foot ulcers: a quality of life issue. Diabetes Metab Res Rev. 2001;17(4):246–9.CrossRefPubMed
16.
go back to reference Aldana PC, Khachemoune A. Diabetic Foot Ulcers: appraising Standard of Care and reviewing New Trends in Management. Am J Clin Dermatol. 2020;21(2):255–64.CrossRefPubMed Aldana PC, Khachemoune A. Diabetic Foot Ulcers: appraising Standard of Care and reviewing New Trends in Management. Am J Clin Dermatol. 2020;21(2):255–64.CrossRefPubMed
17.
go back to reference Levin ME. Preventing amputation in the patient with diabetes. Diabetes Care. 1995;18(10):1383–94.CrossRefPubMed Levin ME. Preventing amputation in the patient with diabetes. Diabetes Care. 1995;18(10):1383–94.CrossRefPubMed
18.
go back to reference Wieman TJ, Smiell JM, Su Y. Efficacy and safely of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21(5):822–7.CrossRefPubMed Wieman TJ, Smiell JM, Su Y. Efficacy and safely of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21(5):822–7.CrossRefPubMed
19.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed
20.
21.
go back to reference Tan TW, Armstrong DG, Concha-Moore KC, Marrero DG, Zhou W, Calhoun E, et al. Association between race/ethnicity and the risk of amputation of lower extremities among medicare beneficiaries with diabetic foot ulcers and diabetic foot infections. BMJ Open Diabetes Res Care. 2020;8(1). Tan TW, Armstrong DG, Concha-Moore KC, Marrero DG, Zhou W, Calhoun E, et al. Association between race/ethnicity and the risk of amputation of lower extremities among medicare beneficiaries with diabetic foot ulcers and diabetic foot infections. BMJ Open Diabetes Res Care. 2020;8(1).
22.
go back to reference Littman AJ, Knott CJ, Boyko EJ, Hawes SE. Associations between racial and ethnic groups and foot self-inspection in people with diabetes. Diabetes Care. 2020;43(5):956–63.CrossRefPubMedPubMedCentral Littman AJ, Knott CJ, Boyko EJ, Hawes SE. Associations between racial and ethnic groups and foot self-inspection in people with diabetes. Diabetes Care. 2020;43(5):956–63.CrossRefPubMedPubMedCentral
23.
go back to reference Jewett DL, King JS. Conduction block of monkey dorsal rootlets by water and hypertonic saline solutions. Exp Neurol. 1971;33(1):225–37.CrossRefPubMed Jewett DL, King JS. Conduction block of monkey dorsal rootlets by water and hypertonic saline solutions. Exp Neurol. 1971;33(1):225–37.CrossRefPubMed
24.
go back to reference Birkenmaier C, Redeker J, Sievers B, Melcher C, Jansson V, Mayer-Wagner S. An evaluation of medications commonly used for epidural neurolysis procedures in a human fibroblast cell culture model. Reg Anesth Pain Med. 2011;36(2):140–4.CrossRefPubMed Birkenmaier C, Redeker J, Sievers B, Melcher C, Jansson V, Mayer-Wagner S. An evaluation of medications commonly used for epidural neurolysis procedures in a human fibroblast cell culture model. Reg Anesth Pain Med. 2011;36(2):140–4.CrossRefPubMed
25.
go back to reference Talbot AR, Herr TM, Parsons DS. Mucociliary clearance and buffered hypertonic saline solution. Laryngoscope. 1997;107(4):500–3.CrossRefPubMed Talbot AR, Herr TM, Parsons DS. Mucociliary clearance and buffered hypertonic saline solution. Laryngoscope. 1997;107(4):500–3.CrossRefPubMed
26.
go back to reference Homer JJ, Dowley AC, Condon L, El-Jassar P, Sood S. The effect of hypertonicity on nasal mucociliary clearance. Clin Otolaryngol Allied Sci. 2000;25(6):558–60.CrossRefPubMed Homer JJ, Dowley AC, Condon L, El-Jassar P, Sood S. The effect of hypertonicity on nasal mucociliary clearance. Clin Otolaryngol Allied Sci. 2000;25(6):558–60.CrossRefPubMed
27.
go back to reference Ural A, Oktemer TK, Kizil Y, Ileri F, Uslu S. Impact of isotonic and hypertonic saline solutions on mucociliary activity in various nasal pathologies: clinical study. J Laryngol Otol. 2009;123(5):517–21.CrossRefPubMed Ural A, Oktemer TK, Kizil Y, Ileri F, Uslu S. Impact of isotonic and hypertonic saline solutions on mucociliary activity in various nasal pathologies: clinical study. J Laryngol Otol. 2009;123(5):517–21.CrossRefPubMed
28.
go back to reference Luk CK, Dulfano MJ. Effect of pH, viscosity and ionic-strength changes on ciliary beating frequency of human bronchial explants. Clin Sci (Lond). 1983;64(4):449–51.CrossRefPubMed Luk CK, Dulfano MJ. Effect of pH, viscosity and ionic-strength changes on ciliary beating frequency of human bronchial explants. Clin Sci (Lond). 1983;64(4):449–51.CrossRefPubMed
29.
go back to reference Eveloff JL, Warnock DG. Activation of ion transport systems during cell volume regulation. Am J Physiol. 1987;252(1 Pt 2):F1–10.PubMed Eveloff JL, Warnock DG. Activation of ion transport systems during cell volume regulation. Am J Physiol. 1987;252(1 Pt 2):F1–10.PubMed
30.
go back to reference Lansley AB, Sanderson MJ, Dirksen ER. Control of the beat cycle of respiratory tract cilia by Ca2 + and cAMP. Am J Physiol. 1992;263(2 Pt 1):L232-42.PubMed Lansley AB, Sanderson MJ, Dirksen ER. Control of the beat cycle of respiratory tract cilia by Ca2 + and cAMP. Am J Physiol. 1992;263(2 Pt 1):L232-42.PubMed
31.
go back to reference Anupam K, Tudu B, Lamay B, Maharaj R. Hypertonic saline: is it the end of normal saline as best irrigant solution in dressing of open trauma wounds? Orthopaedic Proceedings. 2013;95-B(SUPP_1):208-. Anupam K, Tudu B, Lamay B, Maharaj R. Hypertonic saline: is it the end of normal saline as best irrigant solution in dressing of open trauma wounds? Orthopaedic Proceedings. 2013;95-B(SUPP_1):208-.
32.
go back to reference Salomone M, Scalise A, Morozzo U, Ruka E, Fraccalvieri M. The combination of a Hypertonic saline dressing and negative pressure wound therapy (NPWT) for quick and bloodless debridement of difficult lesions in complicated patients. Negative Pressure Wound Therapy Journal. 2015;2(2). Salomone M, Scalise A, Morozzo U, Ruka E, Fraccalvieri M. The combination of a Hypertonic saline dressing and negative pressure wound therapy (NPWT) for quick and bloodless debridement of difficult lesions in complicated patients. Negative Pressure Wound Therapy Journal. 2015;2(2).
33.
go back to reference Attuwaybi B, Kozar RA, Gates KS, Moore-Olufemi S, Sato N, Weisbrodt NW, et al. Hypertonic saline prevents inflammation, injury, and impaired intestinal transit after gut ischemia/reperfusion by inducing heme oxygenase 1 enzyme. J Trauma. 2004;56(4):749–58. discussion 58 – 9.CrossRefPubMed Attuwaybi B, Kozar RA, Gates KS, Moore-Olufemi S, Sato N, Weisbrodt NW, et al. Hypertonic saline prevents inflammation, injury, and impaired intestinal transit after gut ischemia/reperfusion by inducing heme oxygenase 1 enzyme. J Trauma. 2004;56(4):749–58. discussion 58 – 9.CrossRefPubMed
34.
go back to reference Attuwaybi BO, Kozar RA, Moore-Olufemi SD, Sato N, Hassoun HT, Weisbrodt NW, et al. Heme oxygenase-1 induction by hemin protects against gut ischemia/reperfusion injury. J Surg Res. 2004;118(1):53–7.CrossRefPubMed Attuwaybi BO, Kozar RA, Moore-Olufemi SD, Sato N, Hassoun HT, Weisbrodt NW, et al. Heme oxygenase-1 induction by hemin protects against gut ischemia/reperfusion injury. J Surg Res. 2004;118(1):53–7.CrossRefPubMed
35.
go back to reference Delshad E, Tavakkoli-Kakhki M, Motavasselian M. Successful repair of Diabetic Foot Ulcer with Honey-Based treatment: a Case Report. Iranian Red Crescent Medical Journal. 2016;19(3). Delshad E, Tavakkoli-Kakhki M, Motavasselian M. Successful repair of Diabetic Foot Ulcer with Honey-Based treatment: a Case Report. Iranian Red Crescent Medical Journal. 2016;19(3).
36.
go back to reference Gonzalez EA, Kozar RA, Suliburk JW, Weisbrodt NW, Mercer DW, Moore FA. Conventional dose hypertonic saline provides optimal gut protection and limits remote organ injury after gut ischemia reperfusion. J Trauma. 2006;61(1):66–73. discussion – 4.CrossRefPubMed Gonzalez EA, Kozar RA, Suliburk JW, Weisbrodt NW, Mercer DW, Moore FA. Conventional dose hypertonic saline provides optimal gut protection and limits remote organ injury after gut ischemia reperfusion. J Trauma. 2006;61(1):66–73. discussion – 4.CrossRefPubMed
37.
go back to reference Hajtalebi H, Khani-Iurigh H, Hajtalebi H-R. Treatment of Diabetic Foot Ulcer in a 58-year-old Turkman patient based on iranian traditional medicine. Traditional and Integrative Medicine. 2016:151–9. Hajtalebi H, Khani-Iurigh H, Hajtalebi H-R. Treatment of Diabetic Foot Ulcer in a 58-year-old Turkman patient based on iranian traditional medicine. Traditional and Integrative Medicine. 2016:151–9.
38.
go back to reference Moodi H, Akbari A, Ghiasi F, Mahmoudzadeh H, Heidari Z, Rashidi H. The Effect of Vacuum-Compression Therapy (VCT) on the Diabetic Foot Ulcer Healing. J Adv Med Biomed Res. 2006;14(57):15–22. Moodi H, Akbari A, Ghiasi F, Mahmoudzadeh H, Heidari Z, Rashidi H. The Effect of Vacuum-Compression Therapy (VCT) on the Diabetic Foot Ulcer Healing. J Adv Med Biomed Res. 2006;14(57):15–22.
39.
go back to reference Shukrimi A, Sulaiman A, Halim A, Azril A. A comparative study between honey and povidone iodine as dressing solution for Wagner type II diabetic foot ulcers. Med J Malaysia. 2008;63(1):44–6.PubMed Shukrimi A, Sulaiman A, Halim A, Azril A. A comparative study between honey and povidone iodine as dressing solution for Wagner type II diabetic foot ulcers. Med J Malaysia. 2008;63(1):44–6.PubMed
40.
go back to reference Riaz MU, Khan M, Akbar A. Comparison of vacuum assisted closure versus normal saline dressing in healing diabetic wounds. Pakistan J Med Health Sci. 2010;4(4):308–13. Riaz MU, Khan M, Akbar A. Comparison of vacuum assisted closure versus normal saline dressing in healing diabetic wounds. Pakistan J Med Health Sci. 2010;4(4):308–13.
Metadata
Title
Hypertonic saline solution 5% as an effective cost-beneficial alternative to normal saline for wound healing in patients with diabetic lower-extremity ulcers: a randomized controlled trial
Authors
Bizhan Ziaian
Samad Khezri
Armin Amirian
Keivan Ranjbar
Reza Shahriarirad
Mariye Eskandari Kohnaki
Publication date
22-12-2022
Publisher
Springer International Publishing
Keyword
Diabetic Foot
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2023
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-022-01167-0

Other articles of this Issue 1/2023

Journal of Diabetes & Metabolic Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine